missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human ADPRHL2 (aa 36-121) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (88%), Rat (88%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-55521 (PA5-55521. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
ADPRHL2 is a member of the ADP-ribosylglycohydrolase family. The enzyme catalyzes the removal of ADP-ribose from ADP-ribosylated proteins. This enzyme localizes to the mitochondria, in addition to the nucleus and cytoplasm.
Specifications
Specifications
| Accession Number | Q9NX46 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 54936 |
| Name | Human ADPRHL2 (aa 36-121) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | [Protein ADP-ribosylarginine] hydrolase-like protein 2; [Protein ADP-ribosylserine] hydrolase; ADPRHL2; ADP-ribose glycohydrolase ARH3; ADP-ribose glycohydrolase ARH3; poly(ADP-ribose) glycohydrolase ARH3; ADP-ribosylarginine hydrolase like 2; ADP-ribosylhydrolase 2; ADP-ribosylhydrolase 3; ADP-ribosylhydrolase like 2; ADP-ribosylserine hydrolase; ADPRS; AI836109; ARH3; ecto ADP-ribosylhydrolase; LOW QUALITY PROTEIN: poly(ADP-ribose) glycohydrolase ARH3; O-acetyl-ADP-ribose deacetylase ARH3; Poly(ADP-ribose) glycohydrolase ARH3; protein ADP-ribosylarginine hydrolase-like protein 2 |
| Common Name | ADPRHL2 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction